about
Use of metformin in diseases of agingImpact of general and central adiposity on ventricular-arterial aging in women and men.Nitrate's effect on activity tolerance in heart failure with preserved ejection fraction trial: rationale and designImpaired myocardial oxygen availability contributes to abnormal exercise hemodynamics in heart failure with preserved ejection fraction.Galectin-3 in heart failure with preserved ejection fraction. A RELAX trial substudy (Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure).Right heart dysfunction in heart failure with preserved ejection fractionEffects of sildenafil on ventricular and vascular function in heart failure with preserved ejection fraction.Effects of Cardiac Resynchronization Therapy on Cardiac Remodeling and Contractile Function: Results From Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction (REVERSE).Associations of Alterations in Pulsatile Arterial Load With Left Ventricular Longitudinal Strain.Impaired Right Ventricular-Pulmonary Arterial Coupling and Effect of Sildenafil in Heart Failure With Preserved Ejection Fraction: An Ancillary Analysis From the Phosphodiesterase-5 Inhibition to Improve Clinical Status And Exercise Capacity in DiasImpact of chronic changes in arterial compliance and resistance on left ventricular ageing in humans.Getting at the Heart of Central Obesity and the Metabolic Syndrome.Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction: A Multiorgan Roadmap.Heart failure with preserved ejection fraction: current understandings and challenges.The pathophysiology of heart failure with preserved ejection fraction.Invasive hemodynamic characterization of heart failure with preserved ejection fraction.MY APPROACH to heart failure with preserved ejection fraction.Suppression of Tumorigenicity 2 in Heart Failure With Preserved Ejection Fraction.Aortic Waveform Analysis to Individualize Treatment in Heart Failure.Role of Diastolic Stress Testing in the Evaluation for Heart Failure With Preserved Ejection Fraction: A Simultaneous Invasive-Echocardiographic Study.Differential Response to Low-Dose Dopamine or Low-Dose Nesiritide in Acute Heart Failure With Reduced or Preserved Ejection Fraction: Results From the ROSE AHF Trial (Renal Optimization Strategies Evaluation in Acute Heart Failure).Enhanced pulmonary vasodilator reserve and abnormal right ventricular: pulmonary artery coupling in heart failure with preserved ejection fraction.Differential hemodynamic effects of exercise and volume expansion in people with and without heart failure.Comparisons of Noninvasive Methods Used to Assess Exercise Stroke Volume in Heart Failure with Preserved Ejection Fraction.High-Output Heart Failure: A 15-Year Experience.Abnormal right ventricular-pulmonary artery coupling with exercise in heart failure with preserved ejection fraction.Evidence Supporting the Existence of a Distinct Obese Phenotype of Heart Failure With Preserved Ejection Fraction.Lung congestion in chronic heart failure: haemodynamic, clinical, and prognostic implications.Inhaled Sodium Nitrite Improves Rest and Exercise Hemodynamics in Heart Failure With Preserved Ejection Fraction.Low-Flow, Low-Gradient Severe Aortic Stenosis in the Setting of Constrictive Pericarditis: Clinical Characteristics, Echocardiographic Features, and Outcomes.Glucose Homeostasis, Pancreatic Endocrine Function, and Outcomes in Advanced Heart Failure.Impaired Pulmonary Diffusion in Heart Failure With Preserved Ejection Fraction.Response to Letter Regarding Article, “Effects of Sildenafil on Ventricular and Vascular Function in Heart Failure With Preserved Ejection Fraction”.Moving beyond cardio-centricity in heart failure risk stratification.Executive summary of the SCAI/HFSA clinical expert consensus document on the use of invasive hemodynamics for the diagnosis and management of cardiovascular disease.Myocardial iron content and mitochondrial function in human heart failure: a direct tissue analysis.SCAI/HFSA clinical expert consensus document on the use of invasive hemodynamics for the diagnosis and management of cardiovascular disease.Sildenafil, unbridled optimism, and heart failure with preserved ejection fraction.Physiological dead space and arterial carbon dioxide contributions to exercise ventilatory inefficiency in patients with reduced or preserved ejection fraction heart failure.Pulmonary Pressure Assessment with the Total Artificial Heart.
P50
Q26828760-666FC298-321E-4522-9533-CAA2EC7CDDAFQ34324637-234004AD-AF98-436A-9361-7EBC31DBED1EQ35005829-C279FFFB-BE1C-464D-9364-0F0F47CB63C8Q35115055-95CB2FBF-AE01-45A7-AD9D-561436F15795Q35206146-A178BA9C-B651-42B6-9692-D84FE922798BQ35588220-61DBA4E2-73FF-47E4-B274-F631EDDC7F11Q35630046-D5388169-3EC5-4598-9755-D20D2B90A390Q36141770-3C93C283-CBC5-4C10-B7F6-0CDC588B4A32Q36468865-67469991-CBE5-4641-A729-CADB09F3CB99Q36796620-EC11578C-8382-4B77-9B89-E1E21C369D5AQ37000861-F7045780-B073-43E5-BD36-91B425A31EE4Q37015771-16D68084-7F98-4B0B-99C1-65A7CF1E02A6Q37058596-FCD62FA0-EAC3-4986-BCF1-22CEAB9ABE30Q38217344-A5549171-2168-49B7-8F57-E810E6718DC3Q38222648-59E4C328-202C-4BDE-91C4-91728967CB39Q38224332-38BB791E-2803-4470-B27A-975EB11555EAQ38255429-407C7BF0-2AFC-4EEB-8203-EF2309F2C057Q38380593-4E4715AD-6644-45C0-BB73-CBD65388B65BQ38381276-8FB9B2E6-8C18-4ACD-AFA0-1B28BD3B5785Q38382930-D03BE9A0-046B-4364-9FC5-4C17DBAF849EQ38389015-4C19504C-1D41-428C-9982-02C41EF54011Q38413616-227AC6A7-AD76-4332-8616-0E907214BABCQ38421775-0092EF89-89AB-4FA1-89BB-EF321EB784E7Q38804767-FC51959E-5FE4-487B-A945-462CE6B0FC78Q38836623-7B31D459-EBF8-4EEA-8E5E-30EBE64A17FCQ39647469-3F10B466-A301-483F-AA82-33831DD7367EQ40256097-BE0FCD1F-376C-4317-860D-0CE110D97458Q40431837-7946D229-2FFA-4981-BDBB-03D98508FDCCQ41112260-5544EBF8-E2C3-45C1-9000-5D5A1FABB03BQ41585855-39981914-FF95-4CD4-AC68-6B9C118B67C1Q41628097-E0B12196-D6B4-43ED-A8F0-8889F76C86A2Q42741631-663224DF-1276-4F42-879C-7160B9A3C226Q43109461-38FA71B8-05B9-46FC-9B46-BFDDD1007E43Q43480049-0AF18A86-45C5-471D-BABA-7C9CD85A9D9BQ46041056-BE8D0B59-8C7D-4E1C-B63B-0BA076F106DAQ46487624-0A341A88-59FF-4BB2-8BC3-BB6C122C787FQ46928672-8C0C0075-7A1A-4E14-8298-E674C78CCE8EQ47369973-A0E084F1-9869-4C94-B7BF-32B251DEBFEDQ47750384-3F68FE07-6D79-4B20-9083-FE683C1D7056Q47882138-9823E3B1-1CD3-4F40-AA4F-983846D35CBF
P50
description
investigador
@es
researcher
@en
name
Barry A Borlaug
@en
type
label
Barry A Borlaug
@en
prefLabel
Barry A Borlaug
@en
P31
P496
0000-0001-9375-0596